Psychedealia
Did someone forward this newsletter to you?
Sign up here to receive the Morning Rise for free.
 
Viridian Capital finds psychedelic stocks typically trade at 3x book
Viridian Capital Advisors has tried to tackle valuation metrics for companies in the psychedelic industry, despite many having no revenue to speak of. Last week, Viridian looked at five companies in the Viridian Value Tracker database with market caps between $10 million and $100 million to get baseline valuation metrics for the Numinus Wellness (NUMI: TSX)(NUMIF: OTCQX) $4...
 Advertisement
 
Prepping the psychedelic industry for MDMA approval
The closure of ketamine clinics (and how successful ones can serve as a template for future clinics) has raised questions about the future of real estate in psychedelics, especially with a big industry catalyst looming in the distance...
 
Pending Patents: Can Any Company Own Psilocybin?
This story was originally published on January 13, 2022, and has been updated.  On December 20, 2021, breakthrough research at the Usona Institute, a 501(c)(3) non-profit medical research organization based in Madison, Wisconsin, revealed the true crystal forms of pharmaceutical psilocybin...
 Advertisement
 
Psilocybin study for bipolar depression encourages more research
A study published by JAMA Psychiatry on bipolar disorder and psilocybin single-dose treatments is getting a lot of attention. The study was originally published on December 6, 2023...
 Advertisement
 
In Other News
Mind Medicine (NASDAQ: MNMD)  plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the company’s results for the year ended December 31, 2023. Read more here.
Filament Health had the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health’s botanical psilocybin drug candidate designed for the treatment of Substance Use Disorders. Read more here.
FSD Pharma Inc. (NASDAQ: HUGE)(CSE: HUGE) has entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, to offer and sell, from time to time, through Wainwright as a sales agent, Class B Subordinate Voting Shares in the capital of the Company having an aggregate offering price of up to US$11,154,232. Read more here.
 
Facebook Twitter Instagram YouTube RSS
Green Market Report © 2017 – 2024. All rights reserved.
Manage Preference     Subscribe     Advertise
 

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.